Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-04-08

Clinical Trial Update: An Investigation of Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus (SLE) [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the safety and tolerability of NNC0114-0006 in systemic lupus erythematosus. The study has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • NNC0114-0006

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Inflammation, Systemic Lupus Erythematosus | Phase 1 | Status: TERMINATED